These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25205348)

  • 1. Neuroprotective agents target molecular mechanisms of disease in ALS.
    Zhu Y; Fotinos A; Mao LL; Atassi N; Zhou EW; Ahmad S; Guan Y; Berry JD; Cudkowicz ME; Wang X
    Drug Discov Today; 2015 Jan; 20(1):65-75. PubMed ID: 25205348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis.
    Sirianni AC; Jiang J; Zeng J; Mao LL; Zhou S; Sugarbaker P; Zhang X; Li W; Friedlander RM; Wang X
    J Neurochem; 2015 Sep; 134(5):956-68. PubMed ID: 26031348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
    Kumar V; Islam A; Hassan MI; Ahmad F
    Eur J Med Chem; 2016 Oct; 121():903-917. PubMed ID: 27372371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies.
    Wei Y; Zhong S; Yang H; Wang X; Lv B; Bian Y; Pei Y; Xu C; Zhao Q; Wu Y; Luo D; Wang F; Sun H; Chen Y
    Eur J Med Chem; 2024 Jun; 272():116496. PubMed ID: 38759454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.
    Pandya RS; Zhu H; Li W; Bowser R; Friedlander RM; Wang X
    Cell Mol Life Sci; 2013 Dec; 70(24):4729-45. PubMed ID: 23864030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future.
    Harikrishnareddy D; Misra S; Upadhyay S; Modi M; Medhi B
    Rev Neurosci; 2015; 26(2):161-81. PubMed ID: 25720096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies in amyotrophic lateral sclerosis-beyond riluzole.
    Morrison KE
    Curr Opin Pharmacol; 2002 Jun; 2(3):302-9. PubMed ID: 12020475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy in amyotrophic lateral sclerosis.
    Distad BJ; Meekins GD; Liou LL; Weiss MD; Carter GT; Miller RG
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):633-51, xi-xii. PubMed ID: 18625421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis.
    Feng X; Peng Y; Liu M; Cui L
    Neuropharmacology; 2012 Feb; 62(2):1004-10. PubMed ID: 22056419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemals, a new drug candidate, extends lifespan and improves electromyographic parameters in a rat model of amyotrophic lateral sclerosis.
    Nicaise C; Coupier J; Dabadie MP; De Decker R; Mangas A; Bodet D; Poncelet L; Geffard M; Pochet R
    Amyotroph Lateral Scler; 2008 Apr; 9(2):85-90. PubMed ID: 18428000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis.
    Morren JA; Galvez-Jimenez N
    Expert Opin Investig Drugs; 2012 Mar; 21(3):297-320. PubMed ID: 22303913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nortriptyline delays disease onset in models of chronic neurodegeneration.
    Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
    Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glutamate hypothesis in ALS: pathophysiology and drug development.
    Blasco H; Mavel S; Corcia P; Gordon PH
    Curr Med Chem; 2014; 21(31):3551-75. PubMed ID: 25245510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of ALS.
    Münch C; Ludolph AC
    Neurol Neurochir Pol; 2001; 35(1 Suppl):41-50. PubMed ID: 11732279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyotrophic lateral sclerosis--a new role for old drugs.
    Brown RH
    N Engl J Med; 2005 Mar; 352(13):1376-8. PubMed ID: 15800236
    [No Abstract]   [Full Text] [Related]  

  • 18. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA; Mozaffar T
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategic approaches to developing drug treatments for ALS.
    Vincent AM; Sakowski SA; Schuyler A; Feldman EL
    Drug Discov Today; 2008 Jan; 13(1-2):67-72. PubMed ID: 18190866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke.
    Trieu VN; Uckun FM
    Biochem Biophys Res Commun; 1999 May; 258(3):685-8. PubMed ID: 10329446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.